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Department of Ophthalmology, Western Galilee  – Nahariya Medical Center, 
Israel 
1. Introduction 
Glaucoma comprises a group of diseases that have in common a characteristic optic nerve 
and visual field damage and elevated intraocular pressure (IOP) is the main risk factor. The 
IOP depends on the balance between the formation and drainage of aqueous humor. The 
glaucoma can be classified into four main groups: open-angle (OAG), acute angle-closure 
(ACG), secondary and developmental glaucoma. The first two refer to the pathophysiology 
of the disease. 
Drug-induced glaucoma is a form of secondary glaucoma induced by topical and systemic 
medications. The most common one is glucorticoid OAG. Several drugs like antidepressants, 
anticoagulants, adrenergic antagonists, sulpha -based drugs and antiepileptic dugs have been 
reported to produce an acute ACG and especially in those with predisposed angle closure. 
Bilateral simultaneous ACG is extremely a rare entity. Drug-induced uveal effusion causing 
secondary ACG have been reported1-9 involving medications such as topiramate,2,4,6,9 
trimethoprin1 and venlafaxine.3 The mechanism of secondary OAG is usually the 
microscopic obstruction of the trabecular meshwork whereas ACG is induced by uveal 
effusion. The treatment of these two entities is similar to OAG and, it could be medically as 
well as surgical. 
The differential diagnosis, prognosis and several future directions for research will be 
discussed. 
Ophthalmologists should be aware of these types of glaucoma, which to my opinion are 
becoming more common in a busy glaucoma clinic. 
2. Epidemiology 
Armaly as shown that within the general population 5 to 6 % of the healthy subjects will 
develop marked elevation of IOP, 4 to 6 weeks after administration of topical 
dexamethasone or betamethasone eye drops.12 These studies have also shown that these 
numbers are directly related to the frequency of the administration and duration of usage of 
this medication. Increasing usage is related to the increased risk for elevated IOP. At higher 
risk are patients with primary open-angle glaucoma, their first-degree relatives, diabetic 
patients, highly myopic individuals, and patients with connective tissue disease, specifically 
rheumatoid arthritis. In addition, patients with angle recession glaucoma are more 
susceptible to corticosteroid-induced glaucoma. 
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3. Mechanisms of IOP elevation in drug-induced glaucoma  
3.1 Open-angle  
Corticosteroid is a group of drugs that may produce IOP elevation by open-angle 
mechanism. Not all the patients taking steroid will develop this glaucoma. The risk factors 
include preexisting primary open-angle glaucoma, a family history of glaucoma, high 
myopia, diabetes mellitus and young age.13 It has been shown that 18-36% of the general 
population and 46–92% of patients with primary open-angle glaucoma respond to topical 
ocular administration of corticosteroids with an elevation of IOP, usually within 2–4 weeks 
after therapy has been instituted.  
Topically applied eye drops and creams to the periorbital area and intravitreal injections are 
more likely to cause IOP elevation than intravenous, parenteral and inhaled forms. Since 
IOP elevation can be gradual and asymptomatic, patients on chronic corticosteroid therapy 
may remain undiagnosed, which can result in glaucomatous optic nerve damage. Steroid-
induced IOP elevation typically occurs within a few weeks after commencing steroid therapy. 
In most cases, IOP returns spontaneously to the baseline within a few weeks to months 
upon discontinuing the steroid (steroid responders). In rare situations, the IOP remains high 
(steroid-induced glaucoma) that may require prolonged glaucoma medication or even 
surgery. This subject is discussed in details in the chapter on steroid-induced glaucoma.  
3.2 Closed-angle  
Some drugs have contraindications or adverse effects that are related to acute angle-closure 
glaucoma. These drugs will incite an attack in individuals with very narrow anterior 
chamber angles that are prone to occlusion, especially when the pupils are dilated. The 
classes of medications that have the potential to induce angle-closure are topical 
anticholinergic or sympathomimetic pupil dilating drops, tricyclic antidepressants, 
monoamine oxidase inhibitors, antihistamines, anti-Parkinson drugs, antipsychotic 
medications and antispasmolytic agents.  
Sulfonamide-containing medications may induce an ACG by a different mechanism, 
involving the anterior rotation of the cilliary-body. Typically, the angle-closure is bilateral 
and occurs within the first few doses. Patients with narrow or wide open angles are 
potentially susceptible to this rare and idiosyncratic reaction.  
4. Pathophysiology of drug-induced glaucoma  
4.1 Open-angle  
The exact pathophysiology of steroid-induced glaucoma is unknown. It is known that 
steroid-induced IOP elevation is secondary to increased resistance to aqueous outflow. 
Some evidence shows that there could be an increased accumulation of glycosaminoglycans 
or increased production of trabecular meshwork-inducible glucocorticoid response (TIGR) 
protein, which could mechanically at microscopic level obstruct the aqueous outflow. Other 
evidence suggests that the corticosteroid-induced cytoskeletal changes could inhibit 
pinocytosis of aqueous humour or inhibit the clearing of glycosaminoglycans, resulting in 
the accumulation of this substance and blockage of the aqueous outflow. 
4.2 Closed-angle  
Aqueous humor is secreted by the ciliary body and circulates through the pupil to reach the 
anterior chamber angle. (Fig. 1) The pathophysiology of angle-closure glaucoma is usually 
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due to pupillary block, i.e. iris-lens contact at the pupillary border resulting from pupillary 
dilation. 
People at risk for Angle Closure Glaucoma (ACG) are those with hypermetropia, 
microphthalmus and nanophthalmos. Medications have a direct or indirect effect, either in 
stimulating sympathetic or inhibiting parasympathetic activation causing pupillary dilation, 
which can precipitate an acute angle-closure in patients with occludable anterior chamber 
angles. These agents include adrenergic agonists (e.g. β2-specific adrenergic agonists (e.g. 
salbutamol), non-catecholamine adrenergic agonists (e.g. amphetamine, dextroamphetamine, 
methamphetamine and phendimetrazine) and anticholinergics (e.g. tropicamide). Histamine 
H1receptor antagonists (antihistamines) and histamine H2 receptor antagonists (e.g. 
cimetidine and ranitidine) have weak anticholinergic adverse effects. Antidepressants such 
as fluoxetine, paroxetine, fluvoxamine and venlafaxine also have been associated with acute 
angle-closures, which is believed to be induced by either the anticholinergic adverse effects 
or the increased level of serotonin that cause mydriasis.  
Sulfa-containing medications may result in acute angle-closures by a different mechanism. 
This involves the anterior rotation of the ciliary body with or without choroidal effusions, 
resulting in a shallow anterior chamber and blockage of the trabecular meshwork by the iris. 
Pupillary dilation and a preexisting shallow anterior chamber angle are not necessary. The 
exact reason for ciliary body swelling is unknown but it occurs in susceptible individuals. 
Topiramate is a sulfa-containing anticonvulsant. There were reports about patients on 
topiramate developing acute angle-closure. However, a pilot study was conducted in the 
Hong Kong Eye Hospital and the Prince of Wales Hospital recently, which showed that 
short-term use of topiramate, did not induce an asymptomatic angle narrowing. Therefore, 
it was suggested that topiramate induced secondary angle-closure glaucoma may be an all-
or-none phenomenon.  
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Fig. 1. Aqueous humor flow 
Carbamazepine is also an anticonvulsive medication and a mood stabilizer and is primarily 
used in treating of epilepsy, bipolar disorders and trigeminal neuralgia.10 It stabilizes and 
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inactivates the sodium Chan resulting in fewer active channels and fewer excited brain cells. 
It was only reported once as causing this disorder.8 
We had two cases that developed simultaneously acute angle-closure glaucoma 4-6 weeks 
after intake of PO carbamazepine. 
Case no. 1 
A 58-year-old woman presented with a bilateral acute ACG. Her medical history included 
epilepsy treated with carbamazepine (Novartis Pharma BU (Novolog), Basel, Switzerland) 
200 mg once a day for 4 weeks to stabilize her medical status. Eleven years earlier she 
underwent thyroidectomy due to hyperthyroidism.  
The best-corrected visual acuity (BCVA) was 20/80 (with +3.75D) OD and 20/100 (with 
+4.25D) OS. The intraocular pressure (IOP) was 54 OD and 46mmHg OS. Both corneas were 
edematous and the anterior chambers were shallow. Gonioscopy revealed angle closure in 
both eyes and fixed, mid-dilated pupils. Ultrasound biomicroscopy (UBM) showed an 
anterior displaced crystalline lens with extensive irido-lenticular contact and peripheral 
anterior synechiae OU. The axial length was 21.35 mm OD and 21.30 mm OS. B-Scan 
ultrasound showed normal posterior segment OU. 
The patient was treated systemically with PO acetazolamide 250mg, topical timolol maleate 
– dorzolamide HCl and brimonidine tartrate twice a day and the IOP decreased to 18mmHg 
OD and 16mmHg OS .Neodymium: Yttrium-Aluminum-Garnet (Nd: YAG) laser iridotomy 
was successfully performed OU. A week later, the BCVA improved to 20/80 OD and 20/60 
OS, on ocular examination, potent iridotomies, mid dilated pupils with sphincter atrophy, 
mild nuclear sclerosis and normal optic discs were noted. The anterior chamber depth 
measured by Scheimpflug imaging (Pentacam®, Oculus Optikgerate GmbH, Wetzlar, 
Germany) was 1.54mm OD and 1.67mm OS and the volume was 90mm3 and 76mm3 
respectively. The pachymetry was 572μm OD and 568μm. The visual fields 30-2 (Humphrey 
II® automatic perimeter, Allergan-Humphrey, San Leandro, CA) performed two months 
later showed inferior nasal step OU. 
Case no. 2 
A 53-year-old female was admitted due to high IOP simultaneously in both eyes. She was 
hypermetropic since childhood and had amblyopic OS. She suffered from epilepsy and had 
two attacks four and six weeks before being hospitalized for which she received PO 
carbamazepine 200mg/d for five weeks. A day before admission, she experienced severe 
bilateral ocular pain, vomiting and decrease in visual acuity OU.  
Her BCVA was 20/40 with +5.50D OD and 20/100 with + 7.50D OS. The IOP was 54 mmHg 
OD and 49 mmHg OS. Both eyes had edematous cornea, very shallow anterior chamber, iris 
bombe and mid-dilated pupil that were not reacting to light. The anterior chamber had a 
narrow angle 360 degrees OU on UBM (Fig. 2). The posterior poles were normal. The patient 
was treated with topical pilocarpine 2% qid and PO acetazolamide 250mg bid.  
The patient underwent Nd: YAG laser iridotomy OU. Three days later, the BCVA improved 
to 20/25 OD and 20/60 OS. The IOP decreased to 8mmHg OD and 6mmHg OS. The anterior 
chambers’ depth was deepened and patent iridotomies, mild-dilated pupil, clear lens and 
posterior pole with normal optic discs were observed. 
The mechanism of these agents causing bilateral AACG has been attributed to ciliochoroidal 
effusion, which causes forward rotation of the lens–iris diaphragm resulting in a secondary 
angle-closure and increased IOP. This medication and others can produce an excessive 
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amount of aqueous production as well as causing culinary body edema. The common 
denominator to our patients was hypermetropia. Indeed, patients with short axial length, 
such as nanophthalmos and hyperopia have a tendency to develop thickened uvea, which 
can be aggravated by intraocular procedures such as cataract surgery resulting in acute 
ACG.11 
5. Non-steroidal agents associated with glaucoma 
Unlike corticosteroid agents, the list of non-steroidal agents associated with glaucoma is 
wide and diverse (Table 1). 14 The causes of glaucoma associated with these agents are also 
varied. The largest single cause of glaucoma in these patients appears to be an atropine-like 
effect, eliciting pupillary dilatation. This class of agents includes antipsychotropics, 
antidepressants, monoamine oxidase (MAO) inhibitors, antihistamines, antiparkinsonian 
agents, antispasmolytic agents, mydriatic agents, sympathetic agents, and botulinum toxin. 
The pupillary dilatation seen in these cases may be enough to precipitate an attack of angle-
closure glaucoma in patients with narrow angles. 
Concerning open-angle glaucoma, the causes of elevated IOP are much more varied, 
including the release of pigment during the pupillary dilation with subsequent obstruction 
of the trabecular meshwork, and a possible increase of inflow during papillary dilation. As 
an alternative, some agents have been documented to produce an idiopathic swelling of the 
lens, associated with angle closure glaucoma. These agents include the antibiotics sulfa, 
quinine, and aspirin. Some agents directly obstruct the trabecular meshwork, such as the 
viscoelastic agents and silicone oil. 
5.1 The role of psychotropic agents 
Of the antipsychotropic agents on the market today, only perphenazine (Trilafon®) and 
fluphenazine decanoate (Prolixin®) have been documented to cause glaucoma. In both 
instances these were attacks of angle-closure glaucoma. These episodes were felt to reflect 
the anticholinergic effect of these agents on the eyes. 
5.2 The role of antidepressant agents 
Amitryptiline (Elavil® and Amitril®) and imipramine (Tofranil®), which are antidepressant 
tricyclic agents, have been shown to produce attacks of an angle-closure glaucoma. Of the 
non-tricyclic drugs, fluoxetine (Prozac®) and mianserin hydrochloride (Bolvidon®) 15 have 
been documented to be associated with attacks of angle-closure glaucoma. 
5.3 The role of mood-altering agents, such as minor tranquilizers, sedatives, and 
stimulants 
This is a rather diverse class of agents including sedatives such as diazepam (Valium®), 
morphine, barbiturates, and stimulants such as amphetamine and methylxanthines such as 
caffeine and theophylline. Diazepam has been reported to be taken by some patient having 
an attack of angle-closure glaucoma, in the literature there it is believed that this drug 
accentuate the anti cholinergic action on the eye in some rare cases with predisposed ACG . 
Barbiturates, morphine, para-aldehyde, meperidine, reserpine, and phenytoin have not been 
reported to produce an elevated IOP. The amphetamines have not been documented to 
produce an elevated IOP in any patient. 
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5.4 The role of antibiotics 
Sulfa drugs 
Agents that contain sulfa have been well documented to produce an idiosyncratic swelling 
of the lens associated with shallowing of the anterior chamber, retinal edema, and elevated 
IOP. These episodes do not involve the pupil and are not responding to cycloplegic agents. 
This observation has been confirmed by A-scan measurements of the eye during such an 
attack16. 
 
Antipsychotropic agents 
Phenothiazines 
Perphenazine (Trilafon), fluphenazine decanoate (Prolixin)
 
Antidepressants 
Tricyclic agents 
Amitryptiline (Elavil), imipramine (Tofranil) 
Nontricyclic agents 
Fluoxetine (Prozac), mianserin HC1 (Bolvidin) 
 
Monoamine oxidase (MAO) inhibitors 
Phenylzine sulfate (Nardil) 
Tranylcypromine sulfate (Parnate) 
 
Antihistamines 
Ethanolamines 
Orphenadrine citrate (Norgesic) 
 
Antiparkinsonian agents 
Trihexyphenidyl HC1 (Artane) 
 
Antispasmolytic agents 
Propantheline bromide (Pro-Banthine) 
Dicydomine HC1 (Bentyl) 
 
Antibiotics 
Sulfa, quinine 
 
Sympathomimetic agents 
Epinephrine, ephedrine 
Phenylephrine 
Amphetamine 
Hydroxyamphetamine 
 
Mydriatic agents 
All agents 
Surgical agents 
Viscoelastic agents, silicone oil 
 
Botulin toxin 
Cardiac agents 
Disopyramide phosphate (Norpace) 
Table 1. Non-steroidal agents 
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5.5 The role of antiparkinsonian agents 
The anti-Parkinson agents act through two mechanisms: (1) Replenishing diminished stores 
of dopamine in the corpus striatum, and (2) Acting as a strong anticholinergic. Indeed, 
trihexyphenidyl 
HCl (Artane)17 has been documented to precipitate angle-closure glaucoma. This finding is 
felt to reflect the anticholinergic effect of this agent. 
5.6 The role of antispasmolytic agents 
These agents act to reduce both the gastrsecretion and the motility of the stomach. Their 
effect directly reflects their anticholinergic power. Although no attacks of angle-closure 
glaucoma are documented with these agents, propantheline bromide (Pro-Banthine®) and 
dicyclomine HCl (Bentyl®) 18 have been documented to raise the IOP in patients with open-
angle glaucoma probably because of their anticholinergic effect. 
5.7 The role of anesthetic agents 
General anesthesia has always entailed an increased risks to the patient, including the risk of 
elevated IOP and glaucoma. It has always been difficult to separate the various risk factors 
to the patient undergoing general anesthesia. The induction of general anesthesia itself may 
be associated with an elevated IOP from laryngeal spasm, coughing, and wheezing 
associated with endotracheal intubation. Specifically, succinylcholine, ketamine and chloral 
hydrate have been well documented to raise IOP. This effect is felt to be due to an increased 
extra-ocular muscle tone from these agents. 19 The preoperative use of atropine, scopalmine, 
and ephedrine associated with attacks of angle-closure glaucoma following general 
anesthesia. 
5.8 The role of antihistamines in inducing glaucoma 
The antihistamines are a diverse group of agents that can be divided into two classes the H1 
and the H2 antihistamines. The H1 antihistamines block the action of histamine on capillary 
permeability and vascular, bronchial, and other smooth muscles.20 The H2 antihistamines 
block the effect of histamine on the smooth muscle in peripheral blood vessels and secretion 
of gastric acid. This group is important because of their anticholinergic effect of these agents. 
Although the anticholinergic action is mild, orphenadrine citrate (Norgesic®), an H1 
antihistamine, has been documented to precipitate an attack of angle-closure glaucoma. It 
should also be noted that the H1 antihistamine promethazine HCl (Phenergan®) has been 
shown to produce an idiopathic swelling of the lens as documented with the sulfa agents. 
These agents exert only a weak response but should be approached with caution in the 
patient at risk for glaucoma. 
5.9 The role of inhalation agents in inducing glaucoma 
As mentioned above ,a wide variety of agents are found as inhalation products, including 
sympathomimetic and parasympathomimeric agents. Salbutamol and ipratropium (used in 
combination for chronic obstructive airway) have also been documented to precipitate 
attacks of angle-closure glaucoma due to the anticholinergic effect of ipratropium in 
combination with the effect of salbutamol (a β2 adreno receptor agonist) on increrasing 
aqueous humor production.21 Therefore, these agents should be used with caution in 
patients at risk for such an attack of glaucoma. 
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5.10 The role of cardiac agents in inducing glaucoma 
The traditional cardiac agents including digitalis and quinidine do not appear to have any 
effect on the IOP. However, disopyramide phosphate (Norpace®) does appear to have some 
anticholinergic activity and has indeed been documented to produce an attack of angle-
closure glaucoma.22 
5.11 The role of botulinum toxin (Oculinum) 
Botulinum toxin has become popular for the treatment of essential blepharo-spasm and 
extraocular muscle palsy; this injectable agent has been documented to produce an acute 
attack of angle closure glaucoma. The effect of this drug is on the ciliary ganglion, 
producing pupillarymydriasis.23  
5.12 The role of avastin and lucentis 
A series of patients that developed sustained elevation of intraocular pressure (IOP) after 
intravitreal anti-VEGF injection for the treatment of neovascular age-related macular 
degeneration (AMD) is presented un numerous of recent publications24 IOP reflects a 
balance between the rate that fluid flows into the eye and the rate that it exits the eye. If 
inflow increases or outflow decreases, then IOP will go up. Intravitreal injection of drugs, 
such as Lucentis (ranibizumab) or Avastin (bevacizumab), increases the amount of fluid 
within the eye, and hence will increase IOP. Normally, as the excess fluid gradually exits the 
eye over a period of time, the IOP returns to normal. However, there are a growing number 
of cases of patients undergoing Lucentis and Avastin therapy that develop elevation of IOP 
that does not return to normal. 
In a recent study four out of 116 patients with AMD (3.45%) developed sustained elevated 
intraocular pressure (IOP) after multiple intravitreal injections of Avastin (1.5 mg/0.06 mL) 
and/or Lucentis (0.5 mg/0.05 mL). An analysis of 4 cases revealed: None of the patients had 
a previous diagnosis or family history of glaucoma/OHT. Two patients had both 
bevacizumab and ranibizumab injections. Two patients developed OHT after recent 
intravitreal ranibizumab and 2 patients after recent intravitreal Avastin injection. It appears 
that anti-VEGF drugs may, in some persons, lead to sustained elevation of IOP and possible 
glaucoma. It is not clear why this occurs, nor have any risk factors for this adverse effect, 
such as family history of glaucoma, been identified. Nor is it clear whether the IOP elevation 
is permanent, or whether IOP may return to normal after cessation of anti-VEGF injections. 
Glaucoma medications can lower IOP after it has been elevated by anti-VEGF drug use. 
There are some publictions25 which describe the decrease of rubeosis iridis in patients with 
neo-vascular after intra- vitreal Avastin injection and can lead to decrease in IOP within 48 
hours.  
6. Treatment of drug-induced glaucoma  
6.1 Medical: Open-angle  
If the patient's underlying medical condition can tolerate discontinuation of corticosteroids, 
then its discontinuation will usually result in normalization of IOP. In case of topical 
corticosteroid drops, using a lower potency steroid medication, such as the phosphate forms 
of prednisolone and dexamethasone, loteprednol etabonate or fluorometholone should be 
considered. These drugs have a lesser chance to increase the IOP, but they are usually not as 
effective as others. Topical non-steroidal anti-inflammatory medications (e.g., diclofenac, 
ketorolac) are other alternatives do not cause IOP elevation, but they have only a limited 
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anti-inflammatory activity to treat the patient's underlying condition. In the occasional cases 
in which the patient's IOP does not normalize upon the cessation of the steroid or in those 
patients who must continue with treatment, topical anti-glaucoma medications are 
considered. 
6.2 Medical: Closed-angle 
If the etiology of closed angle glaucoma is sulfa containing medications, the increase in IOP 
generally will resolve upon discontinuing the agent. However, severe cases of sulfonamide-
induced angle-closure (i.e. IOP >45 mm Hg) may not respond to discontinuing the offending 
agent. They may respond to intravenous mannitol. Other etiologies of drug-induced angle-
closure are treated similar to primary acute angle-closure glaucoma with topical beta-
blockers, prostaglandin analogues, cholinergic agonists and often oral acetazolamide. 
6.3 Laser treatment  
For open-angle steroid-induced glaucoma, selective laser trabeculoplasty or Argon laser 
trabeculoplasty (Fig. 3) can be applied in the absence of intraocular inflammation if the IOP 
is suboptimal with medication. 
In closed-angle glaucoma, an Argon laser peripheral iridoplasty or YAG laser iridotomy 
may be performed to widen the angle and deepen the anterior chamber. Laser iridotomy can 
be performed to reverse pupillary block or to prevent further pupillary block. Laser 
Irididotomies can be performed as a preventive procedure in hepermetropic naophthalmic 
and microphthalmic eyes. Fig. 4 shows the effect of Argon laser laser iridotomy. When 
medical and laser therapy are ineffective in lowering the IOP to target pressure or the 
patient is intolerant to medical therapy, surgical therapy is indicated. Usually, trabeculectomy, 
a guarded filtration procedure, with or without intraoperative anti-metabolites, is the 
primary procedure. In cases of eyes with active neovascularization or inflammation, a 
glaucoma drainage implant may be used as the primary procedure. 
 
 
Fig. 2. ALT Argon Laser Trabeculoplasy 
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Fig. 3. LI Laser Iridotomy 
6.4 Surgical: Closed-angle  
Trabeculectomy can also be performed with similar indications as open-angle glaucoma. 
However, the surgery is more difficult since the anterior chamber is shallower and the 
cornea is usually hazier due to the acute IOP rise. 
7. Prevention of drug induced glaucoma 
7.1 Open-angle  
Unnecessary prolonged use of cortcosteroid should be avoided. Ophthalmic evaluation is 
recommended for patients treated with long-term steroids especially with risk factors such 
as family history of primary open-angle glaucoma.  
7.2 Closed-angle  
Prophylactic laser iridotomy may be performed in patients requiring frequent mydriasis 
such as frequent fundus examinations for diabetic retinopathy. Agents causing secondary 
angle-closure should be avoided in susceptible individuals as far as possible. 
8. Conclusion  
Drugs that cause or exacerbate open-angle glaucoma are mostly glucocorticoids. Several 
classes of drugs, including adrenergic agonists, cholinergics, anticholinergics, sulpha-based 
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drugs, selective serotonin reuptake inhibitors, tricyclic and tetracyclic antidepressants, 
anticoagulants and histamine H(1) and H(2) receptor antagonists, have been reported to 
induce or precipitate acute angle-closure glaucoma, especially in individuals predisposed 
with narrow angles of the anterior chamber. In some instances, bilateral simultaneous 
development of acute ACG occurs after carbamazepine and topiramate intake may occur 
especially in eyes with short axial length such as hypermetropia, microphthalmia and 
nanophthalmos. Clinicians should be mindful of the possibility of drug-induced glaucoma, 
whether or not the drug is listed as a contraindication and if in doubt, consult an 
ophthalmologist. Patients should visit an ophthalmologist routinely twice a year after the 
age of 40 and inform him about their different medications. 
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